ArticlePloS one2011
Seroprevalence of pandemic influenza H1N1 in Ontario from January 2009-May 2010.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES-I statement): an extension of the STROBE statement.Influenza and other respiratory viruses · 2017Guideline
- Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.Influenza and other respiratory viruses · 2013Pooled it
- The Use of Residual Blood Specimens in Seroprevalence Studies for Vaccine-Preventable Diseases: A Scoping Review.Vaccines · 2025Review
- Evidence of rapid rise in population immunity from SARS-CoV-2 subclinical infections through pre-vaccination serial serosurveys in Pakistan.Journal of global health · 2025Article
- Seroprevalence of influenza A H1N1 (swine) infection in the human population in a cantonment.Medical journal, Armed Forces India · 2019Article
- Trends in Pediatric Complicated Pneumonia in an Ontario Local Health Integration Network.Children (Basel, Switzerland) · 2018Article
- Article
- National assessment of Canadian pandemic preparedness: Employing InFluNet to identify high-risk areas for inter-wave vaccine distribution.Infectious Disease Modelling · 2017Article
- A statistical method utilizing information of imported cases to estimate the transmissibility for an influenza pandemic.BMC medical research methodology · 2017Article
- Article
- Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data.PLoS biology · 2015Article
- Estimating the incidence reporting rates of new influenza pandemics at an early stage using travel data from the source country.Epidemiology and infection · 2014Article
- Article
- Does outpatient laboratory testing represent influenza burden and distribution in a rural state?Influenza and other respiratory viruses · 2013Article
- 2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos.PloS one · 2013Article
- Article
- H3N2v and other influenza epidemic risk based on age-specific estimates of sero-protection and contact network interactions.PloS one · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe designed a seroprevalence study using multiple testing assays and population sources to estimate the community seroprevalence of pH1N1/09 and risk factors for infection before the outbreak was recognized and throughout the pandemic to the end of 2009/10 influenza season.
methodsResidual serum specimens from five time points (between 01/2009 and 05/2010) and samples from two time points from a prospectively recruited cohort were included. The distribution of risk factors was explored in multivariate adjusted analyses using logistic regression among the cohort. Antibody levels were measured by hemagglutination inhibition (HAI) and microneutralization (MN) assays.
resultsResidual sera from 3375 patients and 1024 prospectively recruited cohort participants were analyzed. Pre-pandemic seroprevalence ranged from 2%-12% across age groups. Overall seropositivity ranged from 10%-19% post-first wave and 32%-41% by the end of the 2009/10 influenza season. Seroprevalence and risk factors differed between MN and HAI assays, particularly in older age groups and between waves. Following the H1N1 vaccination program, higher GMT were noted among vaccinated individuals. Overall, 20-30% of the population was estimated to be infected.
conclusionsCombining population sources of sera across five time points with prospectively collected epidemiological information yielded a complete description of the evolution of pH1N1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.